Functional dissection of oncogenic enhancers T cell acute lymphoblastic leukemia (T-ALL) accounts for 10% to 15% of pediatric and 25% of adult T-ALL cases and was originally identified as highly aggressive tumor associated to poor prognosis. Despite recent progress in the treatment of this disease, the prognosis of patients with relapsed and refractory T-ALL remain extremely poor, underscoring the need to identify molecular mechanisms responsible for disease progression and to develop more effective antileukemic drugs. We recently identified N-Me, a NOTCH1-bound enhancer driving MYC expression in T-cells. This enhancer is recurrently amplified in T-ALL and is strictly required for NOTCH1-induced transformation. These results demonstrate a critical role for long-range regulatory sequences in the pathogenesis of NOTCH1-induced T-ALL and highlight the potential for enhancer-driven gene expression mechanisms as a therapeutic target for the treatment of human cancer. Based on our results, we hypothesize that N-Me regulates gene expression in T- ALL by interacting with additional as yet uncharacterized long-range regulatory sequences and via the activity of T-cell lineage specific transcription factors. Moreover, we propose that oncogenic NOTCH1 controls additional key long range enhancers controlling master regulators of the leukemia oncogenic program in addition to MYC and that long range regulatory enhancers play a critical role in the pathogenesis solid tumors. The goal of this proposal is to advance our understanding of the basic mechanisms of long-range transcriptional regulation in human cancer as a first step to ultimately provide new tools and targets for the treatment of this disease. Toward this objective we propose: (i) To analyze the mechanisms of N-Me mediated Myc expression in T-ALL (Aim 1); (ii) To functionally dissect the role of N-Me in the control of Myc expression in vivo using CRISPR/Cas9 genome editing tools (Aim 2); and (iii) To identify NOTCH1-bound enhancers in solid tumors (Aim 3).

Public Health Relevance

N-Me is a NOTCH1-bound MYC enhancer that is critically required for T-cell development and for NOTCH1-induced T-cell leukemia. Our preliminary results show that this oncogenic enhancer is recurrently amplified in human leukemia and is only active in T-cells, underscoring the need to understand what factors confer its T-cell specificity. This project will define the mechanisms of action and regulation of the N-Me enhancer in vivo and will provide novel insights on the basic biology of enhancers and superenhancers, which will ultimately facilitate the development of novel cancer therapies targeting these regions.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Transition Award (R00)
Project #
4R00CA197869-03
Application #
9484553
Study Section
Special Emphasis Panel (NSS)
Program Officer
Jhappan, Chamelli
Project Start
2017-07-01
Project End
2020-05-31
Budget Start
2017-07-01
Budget End
2018-05-31
Support Year
3
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Rbhs -Cancer Institute of New Jersey
Department
Type
Overall Medical
DUNS #
078728091
City
New Brunswick
State
NJ
Country
United States
Zip Code
08901
Lancho, Olga; Herranz, Daniel (2018) The MYC Enhancer-ome: Long-Range Transcriptional Regulation of MYC in Cancer. Trends Cancer 4:810-822
Costa-Machado, Luis Filipe; Martín-Hernández, Roberto; Sanchez-Luengo, Miguel Ángel et al. (2018) Sirt1 protects from K-Ras-driven lung carcinogenesis. EMBO Rep 19:
Sanchez-Martin, Marta; Ambesi-Impiombato, Alberto; Qin, Yue et al. (2017) Synergistic antileukemic therapies in NOTCH1-induced T-ALL. Proc Natl Acad Sci U S A 114:2006-2011
Fabbri, Giulia; Holmes, Antony B; Viganotti, Mara et al. (2017) Common nonmutational NOTCH1 activation in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 114:E2911-E2919